Ernexa posts new fact sheet, presentation

Q: What did Ernexa Therapeutics (ERNA) disclose in the September 16, 2026 Form 8-K?

Ernexa Therapeutics furnished a corporate fact sheet and an investor presentation as Exhibits 99.1 and 99.2, respectively, under an Item 7.01 Regulation FD disclosure. These materials provide investor information and include a “Forward-Looking Statements” section incorporated into this item.

Q: How does Ernexa Therapeutics (ERNA) use its website for investor information?

Ernexa explains it uses its website as a channel of distribution for important information, routinely posting press releases, investor presentations and financial information, and may use the site to provide time‑critical information in advance of or instead of a press release or SEC filing.

Q: Can the furnished investor materials be incorporated into other Ernexa (ERNA) SEC filings?

The company specifies that the furnished information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act, except where a future filing specifically incorporates such information by reference.

Ernexa Therapeutics furnished a new fact sheet and investor presentation and highlighted its website as a key channel for distributing time‑critical company information.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) reported that on September 16, 2026 it made a corporate fact sheet and an investor presentation available to investors, furnished as Exhibits 99.1 and 99.2 to this report under a Regulation FD disclosure.

The company states that these materials, including their “Forward-Looking Statements” disclosure, are incorporated by reference into this Item 7.01 and will also be accessible on its investor relations website starting September 17, 2026. Ernexa explains that it uses its website as a regular channel to distribute important and time‑critical company information, while clarifying that the furnished materials are not deemed filed for purposes of Section 18 of the Exchange Act.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Date of investor materials: September 16, 2026 Website availability date: September 17, 2026 Exhibit 99.1: Ernexa Therapeutics Fact Sheet +1 more

4 metrics

Date of investor materials September 16, 2026 Date of the Ernexa Therapeutics fact sheet referenced as Exhibit 99.1

Website availability date September 17, 2026 Date when the fact sheet and investor presentation will be accessible on the company’s website

Exhibit 99.1 Ernexa Therapeutics Fact Sheet Furnished as part of the Item 7.01 Regulation FD disclosure dated September 16, 2026

Exhibit 99.2 Ernexa Therapeutics Investor Presentation Furnished as part of the Item 7.01 Regulation FD disclosure in September 2026

Key Terms

Forward-Looking Statements, Regulation FD, furnished and not filed, Section 18 of the Securities Exchange Act of 1934

4 terms

Forward-Looking Statements regulatory

"the “Forward-Looking Statements” disclosure contained in the fact sheet and investor presentation"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Regulation FD regulatory

"made available the corporate fact sheet and a presentation for investors under a Regulation FD disclosure"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

furnished and not filed regulatory

"information contained in this Item 7.01 ... is “furnished” and not “filed”"

Section 18 of the Securities Exchange Act of 1934 regulatory

"not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ernexa Therapeutics (ERNA) disclose in the September 16, 2026 Form 8-K?

Ernexa Therapeutics furnished a corporate fact sheet and an investor presentation as Exhibits 99.1 and 99.2, respectively, under an Item 7.01 Regulation FD disclosure. These materials provide investor information and include a “Forward-Looking Statements” section incorporated into this item.

When will Ernexa Therapeutics’ new investor materials be available on its website?

The company states that the corporate fact sheet and investor presentation will be available on its investor relations website, https://investor.ernexatx.com, on September 17, 2026, in addition to being furnished as exhibits to this current report.

How does Ernexa Therapeutics (ERNA) use its website for investor information?

Ernexa explains it uses its website as a channel of distribution for important information, routinely posting press releases, investor presentations and financial information, and may use the site to provide time‑critical information in advance of or instead of a press release or SEC filing.

Are the fact sheet and investor presentation considered filed for Exchange Act Section 18 purposes?

No. Ernexa states that the information in Item 7.01, including Exhibits 99.1 and 99.2, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to that section’s liabilities.

Can the furnished investor materials be incorporated into other Ernexa (ERNA) SEC filings?

The company specifies that the furnished information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act, except where a future filing specifically incorporates such information by reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/16/2026 - 05:31 PM Accepted by SEC EDGAR 09/16/2026 - 05:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2026

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-11460

31-1103425

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1035 Cambridge Street, Suite 18A
Cambridge, MA		02141
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 798-6700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $0.005 per share	ERNA	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	ERNAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On September 16, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), made available the corporate fact sheet and a presentation for investors. Copies of the corporate fact sheet and the presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated by reference in this Item 7.01. Copies of the corporate fact sheet and presentation will also be available on our website at https://investor.ernexatx.com on September 17, 2026.

Without limiting the generality of the foregoing, the “Forward-Looking Statements” disclosure contained in the fact sheet and investor presentation is incorporated by reference into this Item 7.01.

Use of our Website to Distribute Material Company Information

We use our website as a channel of distribution for important Company information. We routinely post on our website important information, including press releases, investor presentations and financial information, which may be accessed by clicking on either the “News” or “Investor Relations” sections of www.ernexatx.com. We may also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (the “SEC”) disclosing the same information. Therefore, investors should look to the “News” or “Investor Relations” sections of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current Report on Form 8-K or in any of our other filings with the SEC.

The information contained in this Item 7.01, including in Exhibits 99.1 and 99.2 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Ernexa Therapeutics Fact Sheet, dated September 16, 2026
99.2		Ernexa Therapeutics Investor Presentation - September 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.